Financial Data and Key Metrics Changes - Supernus achieved record total revenues of $719 million for the full year 2025, representing a 27% increase compared to the previous year [16] - For Q4 2025, total revenue was $211.6 million, a 21% increase year-over-year, and a 34% increase when excluding net product sales of Trokendi XR and Oxtellar XR [13][16] - GAAP net loss for the full year 2025 was $38.6 million, or a loss of $0.68 per diluted share, compared to a GAAP net earnings of $73.9 million, or $1.32 per diluted share in 2024 [17] - Adjusted operating earnings for the full year 2025 were $158.7 million, down from $183.7 million in 2024 [18] Business Line Data and Key Metrics Changes - Revenues from the four growth products (Qelbree, Proquarius, Zerzura, and ONAPGO) accounted for approximately 76% of total revenues in Q4 2025 [4] - ONAPGO generated net sales of $8.9 million in Q4 2025, up from $6.8 million in Q3 2025, with total net sales for its first year at $17.3 million [5] - Zurzuvae had collaboration revenues of $32.8 million in Q4 2025, with U.S. sales increasing approximately 187% compared to Q4 2024 [6] - Qelbree exceeded $300 million in net sales for 2025, delivering 26% growth compared to 2024 [8] Market Data and Key Metrics Changes - The number of prescribers for ONAPGO grew by 28% in Q4 2025 compared to Q3 2025, with prescriptions increasing by 29.6% [5] - The number of prescribers for Zurzuvae doubled in 2025 compared to 2024, with total prescriptions increasing by more than 150% [6] - GOCOVRI reached net sales of $146 million for the full year 2025, a 12% increase compared to 2024 [10] Company Strategy and Development Direction - The company aims to continue growing its core business while exploring corporate development opportunities to strengthen its position in the CNS market [11][76] - Supernus is focused on revenue-generating products and late-stage pipeline candidates, with a strategic emphasis on expanding its portfolio beyond CNS into areas like women's health [72] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving total revenues of $840 million to $870 million for 2026, with expectations of $45 million to $70 million in net sales from ONAPGO [19] - The company anticipates combined R&D and SG&A expenses to range from $620 million to $650 million for 2026 [19] - Management highlighted the importance of maintaining a strong balance sheet with no debt, providing financial flexibility for future growth opportunities [18] Other Important Information - The company initiated a Phase IIb trial for SPN-820 and is progressing with ongoing trials for SPN-817, with data expected in 2027 [11][71] - Supernus has made significant investments in R&D and SG&A, with combined expenses reaching $591.8 million for the full year 2025 [16] Q&A Session Summary Question: ONAPGO supply and sales potential - Management confirmed that the current supplier can meet the $45 million-$70 million sales guidance for ONAPGO, with plans for continuity of supply into 2026 [21] Question: ONAPGO demand and patient enrollment - Management indicated that the current supplier will help clear the backlog and support new patient initiations, with ongoing processing of enrollment forms [28] Question: R&D prioritization post-Sage acquisition - Management stated that early-stage assets will undergo preclinical work, with prioritization based on market opportunity and ROI [29] Question: Zurzuvae commercial strategy - Management emphasized the need to build market awareness and confidence among physicians to drive prescriptions for Zurzuvae [59] Question: Gross-to-net expectations for ONAPGO - Management expects gross-to-net for ONAPGO to be in the range of 20%-30%, typically higher in Q1 [66]

Financial Data and Key Metrics Changes - The company guided for approximately $150 million in sales for the first half of FY 2025, with less than $100 million expected in Q4 [2] - The operating margin improved to roughly 50% in Q3, up from just below 40% previously, indicating strong operational leverage [34][36] Business Line Data and Key Metrics Changes - The HIV prevention business collectively grew 42% year over year, driven by the launch of Sunlenca and the growth of Descovy, which saw a 32% increase in the same period [6][10] - Biktarvy, a key HIV treatment, generated $3.5 billion in sales in Q3, showcasing its strong market position [3][15] Market Data and Key Metrics Changes - The HIV prevention market is estimated to have around 500,000 patients currently on therapy, with the CDC estimating that at least 2.2 million people in the U.S. could benefit from HIV prevention [7][11] - The company noted that the market opportunity for HIV prevention could be much larger, with 10-12 million people diagnosed with sexually transmitted diseases annually in the U.S. [7] Company Strategy and Development Direction - The company is focused on building awareness and changing prescriber habits to promote the shift from daily oral medications to long-acting injectables [2][5] - A patent settlement extended the exclusivity of Biktarvy until at least 2036, allowing the company to plan long-term without immediate competitive pressures [14] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the steady growth of the HIV prevention market and the potential for Sunlenca to capture a significant share [3][10] - The company is confident in its pipeline, with multiple launches expected in the coming years, which will support diversification and growth [29][36] Other Important Information - The company is actively pursuing business development opportunities, particularly in China, where it has seen a shift towards more innovative assets [31][32] - The company plans to continue investing in R&D while maintaining a disciplined approach to operational expenses [34][36] Q&A Session Summary Question: Can you discuss the early demand for Sunlenca? - Management noted that early demand is coming from naive patients and those switching from generic Truvada, with a significant portion also switching from other long-acting injectables [9][10] Question: What is the strategy for educating patients and physicians about Sunlenca? - The company is building a sales force and healthcare educators to work directly with physicians and is planning advertising campaigns to raise awareness [5][11] Question: How does the patent settlement for Biktarvy influence long-term planning? - The extended exclusivity until 2036 allows for strategic planning without immediate concerns about competition, supporting the development of next-generation treatments [14][15] Question: What are the growth opportunities for Anito-cel in multiple myeloma? - The company plans to move Anito-cel into earlier lines of treatment, targeting a sizable market opportunity in both second-line and first-line therapies [24][25] Question: What is the outlook for Trodelvy in triple-negative breast cancer? - Trodelvy is expected to continue growing, especially with label expansion anticipated next year, contributing to sustained growth over time [27]

Core Insights - Jonathan Price transitioned from investment banking to corporate development and ultimately became CFO of Q2 Holdings, reflecting a desire for accountability in business outcomes post-transaction [2][3][6][8] Company Overview - Q2 Holdings is a Texas-based provider of digital transformation solutions for financial services, where Price joined as senior vice president of corporate development in 2018 [3][4] - The company emphasizes a culture fit and strong management, which were key factors in Price's decision to join [3] Career Progression - Price spent 13 years in investment banking before moving to Q2, where he initially focused on corporate and business development [2][8] - His responsibilities expanded to include business development, emerging businesses, and strategy, leading to his appointment as CFO in late 2024 [4][5] Strategic Focus - The shift from investment banking to corporate development allowed Price to take ownership of business outcomes, integrating the advisory role with operational accountability [6][7] - Price's experience in corporate strategy and partnerships provided a solid foundation for his role as CFO, giving him a comprehensive understanding of the company's operations [8]

Summary of Jazz Pharmaceuticals (JAZZ) FY Conference Call - June 11, 2025 Company Overview - **Company**: Jazz Pharmaceuticals (JAZZ) - **Key Speakers**: Phil Johnson (CFO), Rob Yunone (EVP of Global Head of R&D and CMO) Core Industry Insights - **Industry**: Biotechnology and Pharmaceuticals - **Key Products**: Xywav, Epidiolex, prasinezumab, dordavapril, Subselka Key Points and Arguments Business Performance and Growth - Strong growth reported in Q1 for Xywav and the sleep business, as well as Epidiolex, despite some softness in the oncology sector due to one fewer shipping week [4][5] - Upcoming catalysts include launches for prasinezumab in Europe and dordavapril with an August PDUFA date, indicating positive momentum in the oncology business [5][7] - The company maintains a strong financial position with $2.6 billion in cash and $400 million in operating cash flow for the quarter, allowing for continued investment in commercial and pipeline assets [7] Strategic Positioning and Risk Management - The company has taken proactive measures to mitigate potential impacts from tariffs by ensuring sufficient finished goods inventory in the U.S. to cover demand for 2025 [11][12] - Plans to produce Xywav domestically to further buffer against tariff impacts [12][13] CEO Transition and Corporate Development - The search for a new CEO is ongoing, with a focus on finding a candidate who aligns with the company's founding principles of patient impact and workplace culture [14][15] - The company has not paused corporate development activities despite the CEO transition, indicating a commitment to growth and transformation [6][15] Pipeline and R&D Highlights - Significant presentations at ASCO, particularly regarding advancements in small cell lung cancer treatments, with positive results for Tibzelca [17][18] - The company is optimistic about the potential of dirdavaprone and its upcoming PDUFA date [19] Market Dynamics and Competitive Landscape - Xywav has seen net patient additions despite competition, attributed to its low sodium content, which is clinically significant for patients with narcolepsy and idiopathic hypersomnia [44][45] - Anticipation of generic sodium oxybates entering the market, with potential impacts on revenue, but Xywav's safety profile is expected to maintain its competitive edge [48][50][58] Future Opportunities - The commercial outlook for BTC, GEA, and breast cancer is projected to exceed $2 billion, with GEA representing a larger patient population compared to BTC [40][41] - The company is exploring opportunities in the orexin space, with ongoing trials to assess the safety and efficacy of JZP-441 [63][64] Oncology Business Insights - The oncology business faced challenges due to changes in pediatric ALL protocols, but normalization of sales for Rylase is expected as treatment protocols stabilize [69][70] - The company is optimistic about the potential of Subzelca in line maintenance settings, despite recent competition from new entrants [71] Additional Important Insights - The company emphasizes the importance of patient safety and the clinical significance of low sodium content in its products, which is recognized by the FDA [58] - Ongoing discussions with treating physicians indicate a commitment to maintaining the use of Rylase in pediatric settings despite protocol changes [70] This summary encapsulates the key points discussed during the Jazz Pharmaceuticals FY Conference Call, highlighting the company's strategic direction, product performance, and market positioning.